DR. JAMES R DOWNING, MD
Medical Practice in Memphis, TN
License number
Tennessee 17402
Category
Medical Practice
Type
Anatomic Pathology
Address
Address
332 N Lauderdale St., Memphis, TN 38105
Phone
(901) 495-3006
(901) 495-3842 (Fax)
(901) 495-3842 (Fax)
Professional information
President At Recycle Solutions
Position:
President at recycle solutions
Location:
Greater Memphis Area
Industry:
Renewables & Environment
Work:
recycle solutions
-
President
Scientific Director At St. Jude Children's Research Hospital
Position:
Scientific Director at St. Jude Children's Research Hospital
Location:
Greater Memphis Area
Industry:
Research
Work:
St. Jude Children's Research Hospital
-
Scientific Director
Owner, Bluff City Commodities
Position:
Owner at Bluff City Commodities
Location:
Greater Memphis Area
Industry:
Transportation/Trucking/Railroad
Work:
Bluff City Commodities
-
Owner
Dr. James R Downing, Memphis TN - MD (Doctor of Medicine)
Specialties:
Anatomic Pathology
Address:
262 Danny Thomas Pl, Memphis 38105
(901) 495-3006 (Phone), (901) 495-3842 (Fax)
262 Danny Thomas Pl, Memphis 38105
(901) 495-3842 (Fax)
LOUGHRAN MEDICAL GROUP
3411 Silverside Rd STE 103, Wilmington 19810
(302) 479-8464 (Phone), (302) 479-8463 (Fax)
(901) 495-3006 (Phone), (901) 495-3842 (Fax)
262 Danny Thomas Pl, Memphis 38105
(901) 495-3842 (Fax)
LOUGHRAN MEDICAL GROUP
3411 Silverside Rd STE 103, Wilmington 19810
(302) 479-8464 (Phone), (302) 479-8463 (Fax)
Languages:
English
Education:
Medical School
University of Mi Med Sch
Graduated: 1981
University of Mi Med Sch
Graduated: 1981
James R Downing, Memphis TN
Specialties:
Pathologist
Address:
332 N Lauderdale St, Memphis, TN 38105
Methods And Compositions For The Diagnosis And Treatment Of Acute Lymphoblastic Leukemia
US Patent:
2011004, Feb 24, 2011
Filed:
Feb 4, 2009
Appl. No.:
12/866511
Inventors:
James Downing - Memphis TN, US
Charles Mullighan - Memphis TN, US
Charles Mullighan - Memphis TN, US
International Classification:
A01K 67/00, C07H 21/04, C07K 14/47, C12Q 1/68, C07H 21/00, C40B 30/04, G01N 33/68, G01N 33/566
US Classification:
800 13, 536 235, 530350, 435 6, 536 2431, 506 9, 436 86, 435 71, 435 721
Abstract:
Compositions and methods for the identification, prognosis, classification, diagnosis, and treatment of leukemia or a genetic predisposition to leukemia are provided. The present invention is based on the discovery of a novel intragenic deletion in the v-ets erythroblastosis virus E26 oncogene homolog (ERG) allele which is shown herein to be associated with a novel subtype of B-progenitor acute lymphoblastic leukemia (ALL). In one embodiment, the intragenic deletion in ERG results in the expression of C-terminal domain deletion forms of the ERG polypeptide which lacks the DNA-binding PNT domain and CAE domain of the ERG polypeptide and have dominant negative ERG activity. In other embodiments, the intragenic deletions results in a loss of expression of the native ERG polypeptide. Such nucleotide sequences and amino acid sequences of ERG find use in methods and compositions useful in the identification and/or the prognosis and/or predisposition and/or treatment of ALL, more particularly, the novel subtype of B-progenitor AL.
Methods And Compositions For The Diagnosis And Treatment Of Chronic Myeloid Leukemia And Acute Lymphoblastic Leukemia
US Patent:
2010024, Sep 23, 2010
Filed:
Nov 6, 2008
Appl. No.:
12/738759
Inventors:
James Downing - Memphis TN, US
Charles Mullighan - Memphis TN, US
Charles Mullighan - Memphis TN, US
Assignee:
St. Jude Children's Research Hospital - Memphis TN
International Classification:
C12Q 1/68
US Classification:
435 6
Abstract:
Compositions and methods for the identification, prognosis, classification, treatment, and diagnosis of leukemia or a genetic predisposition to leukemia are provided. The present invention is based on the discovery of various genomic abnormalities of the IKZFl gene which are shown herein to be associated with acute lymphoblastic leukemia (ALL), more particularly, associated with BCR-ABL1 positive ALL and/or shown to be associated with chronic myeloid leukemia (CML), more particularly, associated with blast crisis chronic myeloid leukemia (BC-CML) and/or the likelihood of progression into blastic transformation of CML. These various genomic abnormalities of the IKZFl gene can further be used as prognostic markers to identify a subgroup of ALL having very poor outcomes. Such genomic abnormalities of IKZFl find use in methods and compositions useful in the identification and/or prognosis and/or predisposition and/or treatment of ALL, more particularly, BCR-ABL1 positive ALL and/or in the identification and/or prognosis and/or predisposition and/or treatment of CML, more particularly, of BC-CML and/or the likelihood of progression into blastic transformation of CML and/or as prognostic markers to identify a subgroup of ALL having very poor outcomes.